Belgium's Cardio3 Biosciences gets $5.5M to advance heart catheter, stem cell treatment

Belgian outfit Cardio3 Biosciences attracted $5.5 million in new regional government funding. The nondilutive financing will help refinance some debt and also fuel U.S. commercialization plans for C-Cathez, its intramyocardial injection catheter, and its C-Cure stem cell treatment designed to treat heart failure and related ailments. Cardio3 bills the C-Cathez device as a standout that's designed to maximize retention of stem cell treatments in the heart once they're delivered. Cardio3's new funding comes from the Walloon region, and Walloon government minister Jean-Marc Nollet said in a statement that the investment is crucial to keeping up regional leadership in the development of cellular therapies. Item

Suggested Articles

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.